ABSTRACT
Objective:To investigate the effects and the impact on maternal and infant outcome of Tianma-Gouteng Decoction combined low-dose aspirin for high-risk patients with pre-eclampsia (PE). Methods:A total of 94 high-risk patients who met the diagnose cretieria of PE from January 2017 to January 2019 in our hospital were divided into two groups by the random number table method, each group 47 cases. The control group based on symptomatic treatment, received daily 75 mg of aspirin enteric-coated metformin hydrochloride additionally; and the observation group took Tianma-Gouteng Decoction based on the control group. Both groups stopped taking medicine after 28th week of gestation. Immune turbidimetric method was used to detect D-dimer (D-D), the Claus method was used for detecting fibrinogen (Fib). The blood pressure meter was used to measure systolic blood pressure (SBP) and diastolic blood pressure (DBP). The poor maternal and infant outcomes were recorded. Results:After the treatment, the plasma D-D (0.50 ± 0.12 μg/L vs. 0.60 ± 0.30 μg/L; t=2.122, P=0.037), Fib (2.37 ± 0.22 g/L vs. 4.43 ± 0.56 g/L; t=23.473, P<0.01) in the observation group were significantly lower than the control group. The SBP (83.43 ± 4.01 mmHg vs. 96.30 ± 5.34 mmHg, t=13.212), DBP (113.77 ± 3.90 mmHg vs. 126.52 ± 4.43 mmHg, t=14.810) in the observation group were significantly lower than the control group ( P<0.01). The incidence of fetal and neonatal adverse outcomes in the observation group was 10.6% (5/47), the control group was 25.5% (12/47), and there was statistically significant between two groups ( χ2=3.519, P<0.05). The incidence of adverse outcome in the observation group was 31.9% (15/47), the control group was 55.3% (26/47), and there was statistically significant between two groups ( χ2=4.326, P<0.01). Conclusions:Tianma-Gouteng Decoction combined low-dose aspirin enteric-coated metformin hydrochloride can improve coagulation function, lower blood pressure, improve clinical efficacy, reduce the occurrence of advers outcomes for high-risk patients with PE.
ABSTRACT
Objective@#To analyze the clinical features of inpatients infected with influenza A virus, and then to provide evidence for the diagnosis, treatment and prevention of influenza A in primary hospital.@*Methods@#The clinical data of inpatients with influenza A in one district hospital from Dec 2016 to Mar 2017 were collected to analyze retrospectively.@*Results@#A total of 21 665 patients were admitted to hospital from Dec 2016 to Mar 2017. Among them 647 flu-like cases accepted influenza A nucleic acid detection, and 203 cases were positive, the positive rate was 31.4%. The median age of influenza A positive patients was 64.25 years, and 20.2% were 0 to 4 years, 49.26% were 65 years of age or older. 58.13% patients had at least one underlying medical condition. Fever, Cough and Sputum were the most symptoms of patients infected with influenza A. Compared with the patients under 60 years old, non-fever symptoms were more common in those 60 years or older, the difference was statistically significant (χ2=15.43, P<0.001). Laboratory examination indicated that lymphocytopenia were detected in 54.27% of patients, and increased level of C-reactive protein and procalcitonin (PCT) in 74.83% and 11.76% of patients respectively. Moreover, 75.58% of patients had high erythrocyte sedimentation rate (ESR), 8 patients (97.3%) had findings consistent with pneumonia. 78.33% of patients received anti-viral treatment with oseltamivir, the rate of antibiotic utilization was as high as 85.22%. The median of hospitalization expense of patients infected with influenza A was 4 280 (interquartile range 2 792-9 565) yuan, and the cost of inpatients who had combined underlying diseases were higher than that in inpatients who had no coexisting medical conditions, the difference was statistically significant (Z=7.106, P<0.01). No death occurred in this study.@*Conclusions@#Children and old people were at high risk for influenza A infection. Fever, cough and lymphocytopenia were the common clinical features of patients infected with influenza A. It is especially noteworthy for the patients who were 60 years of age or older with flu-like symptoms but without fever, or the patients who had one or more underlying medical conditions, and such patients should receive influenza virus nucleic acid tests as early as possible.